Moderated by IMF Medical Advisor Dr. Joseph Mikhael (TGen at the City of Hope), with panelists Terry Glassman (myeloma patient, high-risk shared experience group co-leader, Long Island NY), Todd and Diane Kennedy (myeloma patient and care partner, City of Hope support group leaders, Southern California). Hosted by Becky Bosley (IMF Senior Director of Support Groups).
The webinar covered five chapters of recent myeloma research from ASCO and EHA, plus a "This Just In" segment on three developments from the past month, followed by audience Q&A. The overarching theme: myeloma outcomes are improving dramatically across all risk groups, and innovation is reaching beyond new drug mechanisms to include delivery, access, and treatment duration.
Workshop chapters Topics Covered in This Workshop
0:00
Opening / Housekeeping / Introductions
7:26
Chapter 1 | Early Relapse: Three Phase III Trials
Three landmark Phase III trials were reviewed, all in patients with 1-3 prior lines of therapy (early relapse).
29:50
Chapter 2 | High-Risk Myeloma
Dr. Mikhael presented a subgroup analysis of MajesTEC-3 led by Rahul Banerjee (Seattle) examining outcomes in cytogenetically high-risk patients (classical high-risk features such as TP53 deletion) and functionally high-risk patients (relapse within 18 months of initial therapy or transplant). At 3 years, standard-risk patients on teclistamab-daratumumab achieved 90% progression-free survival; high-risk patients achieved 80% — a 10-point gap that is far narrower than historically seen, and an absolute number that is itself very impressive. MRD negativity subgroups: 0 high-risk features (90%), 1 feature (82%), 2 features (76%), showing that the high-risk classification remains meaningful but outcomes are improving.
42:38
Chapter 3 | Bispecific Antibodies in the Outpatient Setting
With 75% of myeloma patients treated in community settings, moving bispecifics from inpatient to outpatient management is critical.
55:23
Chapter 4 | Looking Forward: New CAR T Approaches
Three emerging CAR T strategies were reviewed, all with early but striking data.
1:08:44
Chapter 5 | This Just In: New FDA Approvals and Trial Results
Isatuximab On-Body Injector (OBI): A new delivery device — approximately the size of a hockey puck — that administers isatuximab (Sarclisa, CD38 antibody) subcutaneously in 12-13 minutes through a 30-gauge needle.
Iberdomide (Zenbexus): First drug of the CELMoD class to receive FDA accelerated approval, granted on August 13, 2026 — less than a week before the webinar. Approved in combination with daratumumab-hyaluronidase-fihj (generic name of Darzalex Faspro) and dexamethasone for early relapse. Oral pill.
ENDURANCE Trial: Started 13 years ago. In non-high-risk (standard-risk?), non-transplant patients on maintenance lenalidomide after induction, 2 years of maintenance was equivalent to continuing until progression in overall survival — but those on continuous therapy had more side effects. Conclusion: 2 years is likely enough for non-high-risk (standard-risk?) patients.
1:16:35
Chapter 6 | Audience Q&A
1:16:58
Q1 | What does "Oligoclonal" M-spike mean? [01:16:58]
1:17:49
Q2 | Is blood work enough to flag a potential relapse?
1:18:20
Q3 | M-spike at 0.2 since June after starting March — is this remission?
1:19:17
Q4 | How rare is brain plasmacytoma?
1:20:02
Q5 | Why aren't side effects studied more before FDA approval?
1:21:15
Q6 | Can blood/serum replace bone marrow for MRD detection?
1:22:16
Q7 | If on DPd for 3 years and in remission, should I switch to a bispecific?
1:23:01
Q8 | Are insurance companies covering Mezigdomide?
1:23:24
Q9 | Is there quality of life data for these trials?
1:24:05
Q10 | Velcade vs. Revlimid maintenance — when is the right time to stop?
1:26:06
Q11 | Can Mezigdomide or Teclistamab be used after prior daratumumab?
1:27:01
Q12 | Can study results be broken down by myeloma type for high-risk patients?
Speakers:
Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO
IMF Medical Advisor
Terry Glassman
Todd Kennedy
Diane Kennedy
